The effects of polymorphisms in CYP2C19, ATP-binding cassette transporter B1, and paraoxonase-1 on clopidogrel treatment of Uygur patients following percutaneous coronary intervention
ConclusionThe CYP2C19 IMs, PMs, and the number of targeted vessels are essential factors associated with MACE risk in dual clopidogrel-treated Uygur population with ACS following PCI. These data provide valuable insights into the genetic polymorphisms affecting clopidogrel response among minority groups in China.
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Alcoholism | Angioplasty | Aspirin | Bleeding | Cardiology | Cardiovascular | China Health | Clopidogrel | Coronary Angioplasty | Diabetes | Diabetes Mellitus | Drugs & Pharmacology | Endocrinology | Genetics | Heart | Hypertension | Percutaneous Coronary Intervention | Plavix | Smokers